353 related articles for article (PubMed ID: 36426364)
1. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
3. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
4. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
6. Peripheral and central kynurenine pathway abnormalities in major depression.
Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
[TBL] [Abstract][Full Text] [Related]
7. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
[TBL] [Abstract][Full Text] [Related]
9. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
10. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
12. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
[TBL] [Abstract][Full Text] [Related]
14. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
15. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
[TBL] [Abstract][Full Text] [Related]
16. Central levels of tryptophan metabolites in subjects with bipolar disorder.
Trepci A; Sellgren CM; Pålsson E; Brundin L; Khanlarkhani N; Schwieler L; Landén M; Erhardt S
Eur Neuropsychopharmacol; 2021 Feb; 43():52-62. PubMed ID: 33339712
[TBL] [Abstract][Full Text] [Related]
17. Role of the immune-kynurenine pathway in treatment-resistant schizophrenia.
Chen W; Tian Y; Gou M; Wang L; Tong J; Zhou Y; Feng W; Li Y; Chen S; Liu Y; Wang Z; Pan S; Zhang P; Huang J; Yang X; Li CR; Tian L; Hong LE; Tan Y
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Mar; 130():110926. PubMed ID: 38147973
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
19. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
20. A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis.
Tömösi F; Kecskeméti G; Cseh EK; Szabó E; Rajda C; Kormány R; Szabó Z; Vécsei L; Janáky T
J Pharm Biomed Anal; 2020 Jun; 185():113246. PubMed ID: 32182446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
